Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Showing 20 of 27412 trials
Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood
NCT00798226
Active, positions filled
Conditions Asthma, Eczema, Allergy
Phase PHASE1
Enrollment 800
Locations 2 sites
Compensation Phase 1: Typically $1,000-$5,000
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to prevent asthma and allergies in childhood by supplementation with fish oil (n-3 fatty acids) to the mother during pregnancy. Paticipants are mother and children participating in the ABC-(Asthma Begins in Childhood)cohort. Mothers are recruited during pregnancy and receive supplement with n-3 fatty acids or olive oil (placebo) from week 24 of gestation to 1 week after delivery. The child is followed with acute and planned visit at the research unit and diagnosis of disease is done in the research unit according to predefined algorithms.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: n-3 fatty acid — Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
  • Dietary Supplement: olive oil — Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery

Primary Outcomes

  • Persistent wheeze 0 to 3 years of age (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Active, positions filled
Start Date: 2008-11-26
Completion: 2027-07
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: true
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Copenhagen Studies on Asthma in Childhood
Principal Investigators:
  • Klaus Bønnelykke, MD, PhD (PRINCIPAL_INVESTIGATOR) - COPSAC / University of Copenhagen
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Dietary Supplement: n-3 fatty acid — Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
  • Dietary Supplement: olive oil — Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
Study Locations (2 sites)
Copenhagen University Hospital of Copenhagen, Gentofte Municipality, Gentofte 2820 Denmark
Næstved Hospital, Pediatric Department, Næstved, Næstved 4700 Denmark
Eligibility Criteria
Inclusion Criteria (mother): * Pregnant women * Living in Sealand, Denmark * Fluent in Danish Language * Willing to let the newborn child participate in the study Exclusion Criteria (mother): * Participating in other clinical trial
Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis
NCT07503093
Not yet recruiting
Conditions Psychosis, Anxiety, Depression, Ruminati...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this trial is to evaluate the feasibility and preliminary efficacy of using passive smartphone sensors to detect moments of heightened negative mood and inform the timing of brief mental health interventions, such as mindfulness exercises and psychoeducation, in adults with early psychosis.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Smartphone-based Mindfulness Exercise — A brief approximately 1 minute video guided mindfulness based breathing exercise designed to anchor attention to the present moment and reduce negative affect in the moment by guiding participants through a structured breathing technique.
  • Behavioral: Smartphone-based Psychoeducation — A brief text or video based psychoeducation message delivered via the smartphone app. Content covers the nature of emotions and emotion regulation strategies, aimed at improving emotional awareness and coping skills in the moment.
  • Behavioral: Neutral Control Message — A brief text or video based message containing random facts delivered via the MetricWire smartphone app. This serves as an active control condition to allow comparison with the active intervention conditions.

Primary Outcomes

  • Retention Rate (10 weeks)
  • EMA Completion Rate (10 weeks)
  • Participant Acceptability and Satisfaction (Week 10)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-08-01
Completion: 2027-06-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mclean Hospital
Contact Information
Study Contact:
Yoonho Chung, PhD
617-855-2854
ychung3@mgb.org
Justin T Baker, MD, PhD
617-855-3913
jtbaker@mgb.org
Interventions
  • Behavioral: Smartphone-based Mindfulness Exercise — A brief approximately 1 minute video guided mindfulness based breathing exercise designed to anchor attention to the present moment and reduce negative affect in the moment by guiding participants through a structured breathing technique.
  • Behavioral: Smartphone-based Psychoeducation — A brief text or video based psychoeducation message delivered via the smartphone app. Content covers the nature of emotions and emotion regulation strategies, aimed at improving emotional awareness and coping skills in the moment.
  • Behavioral: Neutral Control Message — A brief text or video based message containing random facts delivered via the MetricWire smartphone app. This serves as an active control condition to allow comparison with the active intervention conditions.
Study Locations (1 sites)
McLean Hospital, Belmont, Massachusetts 02478 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-50 years * History of DSM-5 psychotic disorder (e.g., schizophrenia, schizoaffective disorder, psychosis not otherwise specified) * Current elevated mood symptoms, defined as mild or greater depressive symptoms (Patient Health Questionnaire-8 score ≥5) or anxiety symptoms (Generalized Anxiety Disorder-7 score ≥5) * Own a personal iPhone or Android smartphone * Willing and able to provide informed consent * English-speaking Exclusion Criteria: * Active suicidal ideation with both intent and a specific plan. * Current substance use disorder requiring acute treatment * Diagnosis of neurodevelopmental disorder that would impair ability to use smartphone app or complete study procedures * Traumatic brain injury with significant cognitive impairment
Probiotics for Depressive Symptomatology and Neural Activity.
NCT07667530
Not yet recruiting
Conditions Mild-to-moderate Depression, Neural Acti...
Phase NA
Enrollment 76
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate the acute and chronic effects of 16-week probiotic supplementation (Ecologic® Barrier) on depressive symptoms and neural activity in those with mild-to-moderate depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Ecologic® Barrier — Ecologic® Barrier (1x1010 CFU/day).
  • Dietary Supplement: Placebo powder — Matched placebo

Primary Outcomes

  • Leiden Index of Depression Sensitivity - Revised (LEIDS-R) vulnerability/sensitivity for depression. (Baseline and 16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-07-01
Completion: 2027-03-01
Eligibility
Age: 25 Years
Sex: ALL
Volunteers: false
Enrollment: 76 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Reading
Collaborators: Winclove Probiotics B.V.
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Dietary Supplement: Ecologic® Barrier — Ecologic® Barrier (1x1010 CFU/day).
  • Dietary Supplement: Placebo powder — Matched placebo
Study Locations (1 sites)
School of Psychology and Clinical Languages, London, RG6 6UR United Kingdom
Eligibility Criteria
Inclusion Criteria: * Mild to moderate depression symptoms (BDI-II 12-28) * Males and females * Age range will be 25-40 years * Right-handed participants only (required for EEG) Exclusion Criteria: * Taking antidepressants (up to 2 months prior to inclusion) * Undergoing psychological treatment in the form of counselling, therapy or similar (up to 1 month prior to inclusion) * Any diagnosed chronic medical condition (e.g. diabetes) or psychiatric illness. * Use of antibiotics or laxatives (up to 3 months prior to inclusion) * Use of probiotics and/or prebiotics (up to 1 month prior to inclusion) * Enrolled in any other clinical trial (up to 1 month prior to inclusion) * Following restrictive and/or unbalanced diets * Smoking * Continuous use of a weight-loss medication for more than one month prior to screening * Significant gastrointestinal conditions affecting absorption, including but not limited to: inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end-stage renal disease; active cancer or cancer treatment within the past three years
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300
Not yet recruiting
Conditions Depressive Disorder, Major
Phase PHASE3
Enrollment 1000
Locations 169 sites
Compensation Phase 3: Typically $200-$1,000
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if depression symptoms worsen or if withdrawal from the study occurs for any reason.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Brenipatide — Administered SC.
  • Drug: Placebo — Administered SC.

Primary Outcomes

  • Time to Relapse Defined as the Number of Days from Randomization to Date on Which the Participant Meets Any Relapse Criterion of Major Depressive Disorder (MDD) (From Randomization in Double-Blind Adjunctive Treatment to First Relapse For at Least 12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Not yet recruiting
Start Date: 2026-08
Completion: 2029-02
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Interventions
  • Drug: Brenipatide — Administered SC.
  • Drug: Placebo — Administered SC.
Study Locations (169 sites)
University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama 35294 United States
NoesisPharma, LLC, Phoenix, Arizona 85028 United States
Irvine Clinical Research, Irvine, California 92614 United States
Healthy Brain Clinic, Long Beach, California 90804 United States
Oakland Clinical, Oakland, California 94609 United States
Concierge Clinical Trials, Valley Village, California 91607 United States
JEM Research Institute, Atlantis, Florida 33462 United States
Bradenton Research Center, Inc., Bradenton, Florida 34205 United States
Key Clinical Research, Bradenton, Florida 34207 United States
NextPhase Research Florida - Hollywood, Hollywood, Florida 33024 United States
Eligibility Criteria
Inclusion Criteria: * Meet the diagnostic criteria for major depressive disorder * Are on stable standard of care medication for major depressive disorder * Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as * self-inject study intervention * store and use the provided blinded study intervention, as directed * maintain electronic and paper study diaries, as applicable, and * complete the required questionnaires Exclusion Criteria: * Have a lifetime history or current diagnosis of the following: * schizophrenia spectrum or other psychotic disorder * bipolar disorder * borderline personality disorder, or * any eating disorder * Have type 1 diabetes mellitus, or a history of: * ketoacidosis, or * hyperosmolar state or coma. * Evidence of moderate or severe substance or alcohol use disorder within 180 days of screening * Are actively suicidal or deemed a significant risk for suicide * Have participated in a clinical study and received active treatment, or unknown if they received active treatment, within 90 days or 5 half-lives (whichever is longer) before screening
Brief Smartphone Treatment Study
NCT04846777
Recruiting
Conditions Generalized Anxiety Disorder
Phase NA
Enrollment 300
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Little is known about whether and how brief mindfulness therapies yield clinically beneficial effects. This gap exists despite the rapid growth of smartphone mindfulness applications and presence of mental health treatment gap. Specifically, no prior brief, smartphone mindfulness ecological momentary intervention (MEMI) has targeted generalized anxiety disorder (GAD). Moreover, although theories propose that mindfulness intervention can boost attentional control (AC), executive functioning (EF), perspective-taking, and social cognition skills they have largely gone untested. Thus, this randomized controlled trial (RCT) aims to address these gaps by assessing the efficacy of a 14-day smartphone mindfulness EMI (vs. placebo). Participants with GAD will be randomly assigned to either MEMI or self-monitoring placebo (SMP). Those in treatment will exercise multiple core mindfulness strategies (open monitoring, acceptance, attending to small moments, slowed rhythmic diaphragmatic breathing). Also, those in MEMI will be reminded before bedtime that mindfulness is a lifelong practice. Comparatively, participants assigned to SMP will only be prompted to practice self-monitoring. They will notice their thoughts, rate any distress associated with them, and will not be taught any mindfulness strategies. All prompts will occur 5 times a day, for 14 consecutive days. They will complete self-reports and neuropsychological assessments at pre-, post-, and 1-month follow-up. Multilevel modeling analyses will determine if treatment (vs. self-monitoring placebo (SMP)) produces substantially larger reductions in trait worry and negative perseverative cognitions as well as steeper increases in AC and EF (inhibition, set-shifting, working memory updating). In addition, the investigators hypothesized that MEMI (vs. SMP) would lead to greater increases in performance-based and self-reported trait mindfulness, empathy, and perspective taking. Findings will advance understanding of the efficacy of unguided, technology-assisted, brief mindfulness in a clinical sample.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Mindfulness ecological momentary intervention — Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
  • Device: Self-monitoring placebo — Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.

Primary Outcomes

  • Change from Baseline Generalized Anxiety Disorder Symptoms at 14-Day Post-Treatment (Baseline to 14-Day Post-Treatment)
  • Change from Baseline Generalized Anxiety Disorder Symptoms at 6-Week Post-Randomization (Baseline to 6-Week Post-Randomization)
  • Change from Baseline Perseverative Cognitions at 14-Day Post-Treatment (Baseline to 14-Day Post-Treatment)
  • Change from Baseline Perseverative Cognitions at 6-Week Post-Randomization (Baseline to 6-Week Post-Randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2018-11-14
Completion: 2023-07-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Penn State University
Principal Investigators:
  • Nur Hani Zainal, M.S. (PRINCIPAL_INVESTIGATOR) - The Pennsylvania State University
Contact Information
Study Contact:
Nur Hani Zainal, M.S.
917-767-7088
nvz5057@psu.edu
Michelle G. Newman, Ph.D.
814-883-4572
mgn1@psu.edu
Interventions
  • Device: Mindfulness ecological momentary intervention — Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
  • Device: Self-monitoring placebo — Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
Study Locations (1 sites)
The Pennsylvania State University, University Park, Pennsylvania 16802 United States
Eligibility Criteria
Inclusion Criteria: * Presence of Generalized Anxiety Disorder based on the Generalized Anxiety Disorder Questionnaire-IV self-report and Mini International Neuropsychiatric Interview * Current student at the Pennsylvania State University or a community-dwelling adult who expressed interest to participate through the PSU StudyFinder portal * Expressed interest to seek treatment * Currently not receiving treatment from a mental health professional * Able to provide consent * Proficient in English Exclusion Criteria: * Below age 18 * Failure to meet any of above inclusion criteria * Participant currently undergoing * Presence of suicidality, mania, psychosis, or substance use disorders
Neural Correlates of Suicidal Behavior in Youth
NCT07568054
Not yet recruiting
Conditions Suicidal Ideation, Suicide Attempt, Suic...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study, titled "Neural Correlates of Suicidal Behavior in Youth: a Pre and Post CAMS Therapy Neuroimaging Study," aims to better understand the brain mechanisms underlying suicidal thoughts and behaviors in adolescents and young adults (ages 14-24). Suicide is a leading cause of death in this population, and current clinical approaches often fail to accurately predict or prevent suicidal behavior. This study seeks to identify objective neurobiological markers associated with suicide risk and treatment response. Participants will be divided into three groups: (1) high-risk individuals recently hospitalized following a suicide attempt, (2) medium-risk individuals with chronic suicidal ideation but no attempts, and (3) low-risk healthy controls. All participants will undergo advanced neuroimaging, including magnetoencephalography (MEG) and magnetic resonance imaging (MRI), along with comprehensive psychiatric assessments. The study focuses on brain regions and networks implicated in suicidality, including the anterior cingulate cortex and salience network, as well as neurochemical markers such as glutamate. It also examines electrophysiological activity and functional connectivity patterns associated with suicidal thoughts and behaviors. High-risk participants will receive an evidence-based psychotherapy called the Collaborative Assessment and Management of Suicidality (CAMS). This therapeutic approach emphasizes collaboration between patient and clinician to identify and address the underlying drivers of suicidal thoughts, with a focus on increasing hope and reducing psychological distress. Neuroimaging and clinical assessments will be repeated after completion of CAMS to evaluate treatment-related changes. The study's primary goals are to: * Identify neural and electrophysiological correlates of suicide risk. * Distinguish biological differences between individuals with suicidal ideation and those who have attempted suicide. * Determine how CAMS therapy affects brain function and neurochemistry. By integrating clinical and neurobiological data, this research aims to improve understanding of suicidality, enhance risk prediction, and inform more effective, personalized interventions for at-risk youth.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: CAMS — CAMS weekly sessions will be started immediately as an inpatient at the start of the study for the high risk participants. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk \< 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).

Primary Outcomes

  • MRS & suicidality (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-10-30
Completion: 2031-10-01
Eligibility
Age: 14 Years
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Cleveland Clinic
Collaborators: MQ Mental Health Research
Principal Investigators:
  • Tatiana Falcone, M.D. (PRINCIPAL_INVESTIGATOR) - The Cleveland Clinic
Contact Information
Study Contact:
Christina A Deisz, LISW-S
(440) 225-6193
deiszc@ccf.org
Tatiana Falcone, M.D.
(216) 444-7459
falcont1@ccf.org
Interventions
  • Behavioral: CAMS — CAMS weekly sessions will be started immediately as an inpatient at the start of the study for the high risk participants. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk \< 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
Study Locations (1 sites)
The Cleveland Clinic, Cleveland, Ohio 44195 United States
Eligibility Criteria
Inclusion Criteria: * Subjects must be 14-24 years old * Subjects must be: * High Risk Subjects: Psychiatrically admitted due to a suicide attempt or history of 2 previous suicide attempts * Medium Risk Subjects: Suicide ideation for the past year with no suicide attempt * Minimal Risk Subjects: No previous history of suicidal ideation or behavior, not taking any psychiatric history or medication, and no family history of suicide * Subjects must have the ability to understand and the willingness to sign a written informed consent/assent document * Subjects must be English speaking Exclusion Criteria: * Subjects with known history of Autism Spectrum Disorder; non-verbal patients * Subjects with moderate or severe intellectual disability (IQ less than 70 and those patients in special education classes full time) * Subjects with Schizophrenia or history of any type of psychosis including mood related psychosis and brief reactive psychosis * Within 6 months before initial screening, urine toxicology positive for phencyclidine, cocaine or amphetamines (subjects prescribed amphetamines for the management of ADHD will not be excluded) * Subjects with a history of moderate or severe substance or alcohol use per DSM-5 criteria in the past 6 months * Subjects who are currently pregnant or breastfeeding * Subjects in custody of Children's Services * Subjects with recent bone, tendon, spine or joint surgery * Subjects with recent metallic dental implants * Subjects weighing less than 30 kg or more than 200 kg
The Correlation Characteristics Between Mental Health and Gut Microbiota of College Students in Qingyuan Vocational Education City
NCT06595095
Not yet recruiting
Conditions Depression, Anxiety
Phase Not Applicable
Enrollment 600
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about the mental health status and gut microbiota characteristics of college students in Qingyuan Vocational Education City. The main question it aims to answer is: How is the mental condition of college students in Qingyuan Vocational Education City? Is there a correlation between the mental condition and the microbial characteristics of college students in Qingyuan Vocational Education City? Participants will answer online survey questions about their demographic characteristics, disease history, gastrointestinal status, lifestyle habits, and psychological health information. 200 participants from each of the following groups will be included: healthy individuals, anxious Individuals and depressive Individuals. Fecal samples will be collected for microbiome testing and analysis to obtain their microbial characteristics and to analyze the impact of mental health status on microbial changes.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Microbiota Characteristic Data (2024.10-2025.9)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Not yet recruiting
Start Date: 2024-10-01
Completion: 2025-09-10
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhujiang Hospital
Principal Investigators:
  • Yan He, Doctor (PRINCIPAL_INVESTIGATOR) - Southern Medical University, China
Contact Information
Study Contact:
Yumei Liu, Master
18810795365
liuyumei1007@163.com
Interventions
N/A
Study Locations (1 sites)
Zhujiang hospital of southern medical university, Guangzhou, Guangdong 510280 China
Eligibility Criteria
Inclusion Criteria: Healthy Individuals: 1. Ages 18 to 25 years old. 2. Resident in the local area for more than one month. 3. No obvious signs or symptoms of disease. 4. Good psychological condition. 5. College students currently enrolled in Qingyuan Vocational Education City. 6. Having signed an informed consent form, willing to provide relevant survey information and fecal samples. Anxious Individuals: 1. Ages 18 to 25 years old. 2. Resident in the local area for more than one month. 3. Self-rating anxiety scale score greater than or equal to 50. 4. College students currently enrolled in Qingyuan Vocational Education City. 5. Having signed an informed consent form, willing to provide relevant survey information and fecal samples. Depressive Individuals: 1. Ages 18 to 25 years old. 2. Resident in the local area for more than one month. 3. Self-rating depression scale score greater than or equal to 53. 4. College students currently enrolled in Qingyuan Vocational Education City. 5. Having signed an informed consent form, willing to provide relevant survey information and fecal samples. Exclusion Criteria: 1.Pregnant and Lactating Women.
Effect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery
NCT07367542
Not yet recruiting
Conditions Depression, Anxiety, S-ketamine, Breast ...
Phase NA
Enrollment 218
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

A Dual-Center, Randomized, Controlled, Blinded, Prospective Study on the Effects of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Esketamine 0.3mg/kg — A single dose of 0.3 mg/kg esketamine is administered intravenously during anesthesia induction, with the infusion completed over 40 minutes.
  • Drug: Normal Saline — Receiving the same volume of normal saline during induction of anesthesia during the same time

Primary Outcomes

  • Perioperative anxiety and depreession (Preoperative day 1, postoperative day 3, day 7 and day 30)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-01-17
Completion: 2027-02-01
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 218 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese PLA General Hospital
Collaborators: Beijing 302 Hospital
Contact Information
Study Contact:
WEIDONG MI
133810829
wwdd1962@163.com
Weidong Mi Mi
13381082966
wwdd1962@163.com
Interventions
  • Drug: Esketamine 0.3mg/kg — A single dose of 0.3 mg/kg esketamine is administered intravenously during anesthesia induction, with the infusion completed over 40 minutes.
  • Drug: Normal Saline — Receiving the same volume of normal saline during induction of anesthesia during the same time
Study Locations (1 sites)
First Medical center of Chinese PLA General Hospital, Beijing, China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years. 2. Scheduled to undergo elective breast cancer resection surgery. 3. American Society of Anesthesiologists (ASA) physical status classification of I-III. 4. Clearly understand and voluntarily agree to participate in the study, and sign the informed consent form. 5. Anticipated anesthesia duration greater than 90 minutes. Exclusion Criteria: 1. Patients with significant preoperative abnormalities in cardiac, pulmonary, hepatic, or renal function, or coagulation disorders . 2. Patients taking antipsychotics, antidepressants, or glucocorticoids, or with a history of alcohol abuse or illicit drug use . 3. Patients with an MMSE score \<18, dementia, intellectual disability, or those unable to communicate (e.g., coma, severe dementia, hearing or language impairment) . 4. Patients with a history of psychiatric or neurological disorders (e.g., schizophrenia, epilepsy, Parkinson's disease, or severe myasthenia gravis) . 5. Patients with poorly controlled or untreated hypertension (≥180/110 mmHg) . 6. Patients with elevated intracranial or intraocular pressure. 7. Patients with untreated or inadequately treated hyperthyroidism . 8. Patients with a known allergy to the drugs involved in this study . 9. Patients unable to complete the assessment scales required by this study. 10. Patients who are currently participating in other clinical trials
Identity-Based Transdiagnostic Therapy for Young People With Anxiety and Depression
NCT06384196
Recruiting
Conditions Depression, Anxiety
Phase NA
Enrollment 138
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Depression and anxiety are the most prevalent mental disorders among both the general population and young adults, and transdiagnostic treatments for these patients are mostly based on cognitive-behavioral therapy (CBT). Based on common (transdiagnostic) principles of treatment (e.g., emotional exposure), these approaches have proliferated and demonstrated their efficacy in comparison to disorder-specific treatments. Although there are a few transdiagnostic approaches for children and adolescents, it was not possible to not find anyone targeting young people. For this reason, the investigators proposed the Identity-Based Transdiagnostic Therapy (IBTT) as a new treatment modality ideally created to address the challenge of improving the outcomes of psychotherapy for young adults with anxiety and/or depression. The IBTT is a psychological treatment for emotional disorders specifically designed for the youths in terms of their attitudes to treatment (attractiveness, engagement), and highly personalized to their construal of self and others. This project will allow testing the hypothesis that a novel brief psychotherapeutic intervention, IBTT, will be more efficacious in the treatment of the anxiety and/or depression of young adults than the well-established CBT-based Unified Protocol.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Identity-Based Transdiagnostic Therapy (IBTT) — In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.
  • Behavioral: Unified Protocol — In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.

Primary Outcomes

  • Depression, Anxiety and Stress Scales (DASS-21) (DASS-21 will be administered at baseline, at 16 weeks (at completion), and at three-month follow-up.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-02
Completion: 2026-11-02
Eligibility
Age: 16 Years
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Barcelona
Collaborators: Badalona Serveis Assistencials, Nou Barris Mental Health Center, Fundación Sanitaria Sant Pere Claver
Principal Investigators:
  • Guillem Feixas, PhD (PRINCIPAL_INVESTIGATOR) - University of Barcelona
Contact Information
Study Contact:
Guillem Feixas, PhD
+34933125100
gfeixas@ub.edu
Interventions
  • Behavioral: Identity-Based Transdiagnostic Therapy (IBTT) — In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.
  • Behavioral: Unified Protocol — In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.
Study Locations (2 sites)
Badalona Serveis Assistencials, Badalona, 08911 Spain
Associació Centre Higiene Mental Nou Barris, Barcelona, 08042 Spain
Eligibility Criteria
Inclusion Criteria: • Participants with symptoms of depression and/or anxiety as their primary complaint. Exclusion Criteria: * Participants with post-traumatic stress, bipolar and substance use disorders, psychotic symptoms, organic brain dysfunction, marked suicidal ideation and/or intellectual disability. * Participants receiving psychological treatment, unless it is suspended at the time of inclusion in the study itself in agreement with their therapist. * Participants for whom the use of virtual reality may pose a risk, even a minor risk (epilepsia, acute otorhinolaryngological processes or recent interventions, severe cardiovascular disease, unstable hypertension, and pregnancy). * Participants with substantial visual, hearing, and cognitive deficits. * Participants who do not have enough competence to communicate in Spanish or Catalan.
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
NCT07266545
Recruiting
Conditions Unipolar Depression, Bipolar Depression
Phase PHASE4
Enrollment 120
Locations 1 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Vortioxetine — Vortioxetine, once daily, for 8 weeks
  • Drug: Cariprazine (Augmentation Phase) — Participants who do not meet remission criteria will enter a second 8-week augmentation phase (Weeks 9-16). During this phase, cariprazine will be added to the existing regimen, administered orally once daily in the morning, starting at 1.5 mg/day and titrated up to 3.0 mg/day in one week.

Primary Outcomes

  • Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score (Baseline, Week 2, Week 8, Week 10, Week 16)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-02-17
Completion: 2030-12-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Aysegul Ozerdem, MD, PhD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
  • Deniz Ceylan, MD, PhD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Scott E. Feeder
507-255-1975
feeder.scott@mayo.edu
Interventions
  • Drug: Vortioxetine — Vortioxetine, once daily, for 8 weeks
  • Drug: Cariprazine (Augmentation Phase) — Participants who do not meet remission criteria will enter a second 8-week augmentation phase (Weeks 9-16). During this phase, cariprazine will be added to the existing regimen, administered orally once daily in the morning, starting at 1.5 mg/day and titrated up to 3.0 mg/day in one week.
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria Participants must meet all the following criteria to be eligible for the study: 1. Adult females and males, aged 18-65 years 2. Must have the capacity to understand study procedures, to comply with them for the entire length of the study, and to provide informed consent. 3. Current major depressive episodes associated with MDD, BD-I, or BD-II, confirmed using the SCID-IV-CV. If a participant has already completed a structured diagnostic interview within the last 2 years or participated in any of the following studies and provided consent to use their information in future studies: (IRB 19-001722, IRB: 23-004500, IRB: 24-013228, IRB: 25-005856, IRB: 25-007244), those SCID results can be used for the EDIT-ANDRE study. 4. Symptom severity score on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) \> 10. 5. Ability to travel for assessment visits. 6. Negative urine pregnancy test for people of childbearing potential 7. People of childbearing potential must be using an acceptable method of birth control during the study, such as hormonal contraception, intrauterine device, bilateral tubal ligation, partner's documented vasectomy, or complete abstinence from intercourse with childbearing potential, with barrier methods permitted only when used in combination with one of these primary methods. 8. BD-I patients must be on stable dose of at least one mood stabilizer (i.e., lithium, valproate, or a mood-stabilizing atypical antipsychotic at least for one month) at the time of enrollment. Patients with BD-II who enroll in the study while currently taking a mood stabilizer (including lithium, valproate, or lamotrigine) must have been on a stable dose of that medication for a minimum of one month before enrollment. Exclusion Criteria All candidates meeting any of the following criteria at baseline will be excluded from study participation: 1. Individuals who cannot understand English will not be enrolled because informed consent, study procedures, and interviews require comprehension of English. 2. Inability to provide written, voluntary informed consent due to but not limited to being under conservatorship, guardianship, commitment, or currently undergoing involuntary psychiatric hospitalization. 3. Failure to score at least 75% on a 4-item comprehension assessment related to study goals, risks, and benefits 4. For BD-I: not having used at least one mood stabilizer (e.g., lithium, valproate, or mood-stabilizing antipsychotics) at a stable dose and within a therapeutically effective antimanic range for a minimum of one month. 5. History of treatment-refractory depression, defined as non-response to two or more antidepressant or mood-stabilizing regimens despite adequate dose, duration, and adherence during the current episode. 6. Participants with active suicidal ideation, defined as a MADRS item #10 score greater than 4 or a "yes" response to item #4 (ideation with intent) or item #5 (ideation with plan) on the C-SSRS, will be excluded 7. A medically serious suicide attempt within the past 6 months, defined as requiring emergency department evaluation, a medical procedure, or admission to a hospital (e.g., internal medicine, cardiology, or ICU) 8. Current use of monoamine oxidase inhibitors or use within 14 days following discontinuation of a monoamine oxidase inhibitor 9. Presence of mixed symptoms of depression, defined as a YMRS score ≥12 10. Current use of any of the study medications (e.g., vortioxetine, or cariprazine) at the time of enrollment (previous use of these medications is acceptable) 11. Prior hypersensitivity reaction to any of the study medications or documented non-response to any of the study medications at the maximum therapeutic dose 12. A history of seizure disorder 13. Recent use of long half-life psychotropic medications, including fluoxetine (in patients with BD and MDD) and long acting injectable forms of antipsychotics (mainly in BD II and MDD) within the past 4 weeks. 14. Active psychosis, defined as a YMRS item #8 score \>4 or diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or schizophreniform disorder as determined by structured clinical interview 15. Current drug or alcohol use disorder (excluding nicotine); full remission for at least 3 months is required for eligibility 16. Positive toxicology screen for illicit substances (e.g., cocaine, methamphetamine, illegal opiates). Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less. 17. Individuals who are pregnant, lactating, trying to conceive, or not using adequate contraception (e.g., hormonal contraception, intrauterine device, tubal ligation, or condoms) 18. Any active or unstable medical condition judged by the principal investigator to confer excessive risk 19. Clinically significant laboratory abnormality, uncontrolled hypertension (blood pressure \>160/100 mmHg), or tachycardia (heart rate \>110 bpm) 20. Significant renal, hepatic, or cardiac disease; malignancy; autoimmune disease; or chronic kidney disease \> stage IIIa (estimated GFR \< 60 mL/min/1.73 m²) 21. History of traumatic brain injury defined as loss of consciousness for 5 minutes and related to a trauma event 22. Gastric bypass, specifically Roux-en-Y 23. Clinical current diagnosis of delirium, encephalopathy, intellectual disability or cognitive disorder (mild or major neurocognitive disorder) 24. Currently receiving electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), or deep brain stimulation (DBS) as acute or maintenance treatment 25. Current use of systemic steroids, chemotherapy, and radiotherapy 26. Daily use of lorazepam (Ativan) \>4 mg/day, or equivalent doses of other benzodiazepines (e.g., clonazepam \>1 mg, alprazolam \>2 mg, diazepam \>20 mg) 27. No access to smartphones, internet 28. Other Axis I or II diagnoses, by clinical judgments that are the current reason for treatment evaluation or play a large part of the current symptom presentation 29. Ongoing treatment with opioid agonists will constitute an exclusion criterion. In contrast, other ongoing treatments, such as alcohol relapse prevention agents or ADHD pharmacotherapy, will not be considered exclusion criteria, provided that no treatment initiation or significant dose adjustment has occurred within the past 4 weeks. All candidates meeting any of the following criteria at baseline will be excluded from the Phase 2 (cariprazine add-on) of the study: 1. Meeting symptomatic remission criteria based on MADRS (≤ 10). 2. Current use of a strong or moderate CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, fluconazole, or verapamil) strong or moderate CYP3A4 inducer (e.g., carbamazepine, rifampin, phenytoin, or St. John's Wort), due to potential pharmacokinetic interactions with cariprazine. 3. Diagnosis of BD-I with concurrent use of an antipsychotic agent as a mood stabilizer.
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
NCT07745569
Not yet recruiting
Conditions PTSD, PTSD - Post Traumatic Stress Disor...
Phase PHASE2
Enrollment 150
Locations 0 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

PRE-EMPT will assemble a cohort of 150 participants from three populations (low risk, intermediate risk, and high risk for self-harm). We will obtain clinical assessments, structural and functional MRI utilizing tasks pioneered by our team to assess cognitive control (CC) and emotion regulation (ER), and peripheral circular RNA (circRNA) levels to characterize the molecular brain states associated with behavioral risk. The clinical, imaging, and transcriptomic data will be fused and jointly analyzed to increase the accuracy of our risk prediction models. PRE-EMPT in three separate Aims will then prospectively assess three promising and innovative interventions for their potential to reduce suicidal ideation and alter activity in key neural networks: 1) neurofeedback (NF) using real-time fMRI with simultaneous electroencephalography (EEG), 2) a form of transcranial magnetic stimulation (TMS) called accelerated intermittent theta burst stimulation (aiTBS) with dose optimization through electric field modeling; and 3) psilocybin assisted therapy (PSI), with flexible dosing plan to maximize the depth of psychedelic experience. These therapies were chosen based on our team's prior work in all three interventions demonstrating rapid action and large effects.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Transcranial Magnetic Stimulation — This intervention will deliver open-label aiTBS, an efficient FDA-cleared form of rTMS for major depressive disorder to patients with intermediate/high risk (i.e., significant depression and anxiety; chronic suicidal ideation). The study team will conduct modeling of the electric field intensity and distribution for each participant, and provide proof of concept for an electric-field informed dosing strategy that engages brain networks.
  • Drug: Psilocybin (drug) — In this intervention, open-label flexible-dosing of psilocybin assisted therapy in intermediate and high-risk patients will be delivered to reduce suicidal ideation and identify mediators of response. The study team will deliver two separate psilocybin sessions accompanied by preparation and integration therapy. Factors such as dose, depression severity, serotonergic use, and depth of mystical experiences will be correlated with suicidality reduction.
  • Behavioral: Neurofeedback — This intervention will deliver active or sham real-time fMRI neurofeedback occurring across two visits to a low-to-intermediate risk population, i.e., low-to-severe levels of depression or anxiety/PTSD identified by clinical scales, with suicidal ideation present but no intent or plan.

Primary Outcomes

  • Neurofeedback (From enrollment through post-treatment visit about 6-8 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Not yet recruiting
Start Date: 2026-08-31
Completion: 2030-06-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of New Mexico
Collaborators: United States Department of Defense, The Mind Research Network
Principal Investigators:
  • Davin Quinn, MD (PRINCIPAL_INVESTIGATOR) - University of New Mexico
Contact Information
Study Contact:
Crystal A Garcia
505-272-9552
crabaca@salud.unm.edu
Interventions
  • Device: Transcranial Magnetic Stimulation — This intervention will deliver open-label aiTBS, an efficient FDA-cleared form of rTMS for major depressive disorder to patients with intermediate/high risk (i.e., significant depression and anxiety; chronic suicidal ideation). The study team will conduct modeling of the electric field intensity and distribution for each participant, and provide proof of concept for an electric-field informed dosing strategy that engages brain networks.
  • Drug: Psilocybin (drug) — In this intervention, open-label flexible-dosing of psilocybin assisted therapy in intermediate and high-risk patients will be delivered to reduce suicidal ideation and identify mediators of response. The study team will deliver two separate psilocybin sessions accompanied by preparation and integration therapy. Factors such as dose, depression severity, serotonergic use, and depth of mystical experiences will be correlated with suicidality reduction.
  • Behavioral: Neurofeedback — This intervention will deliver active or sham real-time fMRI neurofeedback occurring across two visits to a low-to-intermediate risk population, i.e., low-to-severe levels of depression or anxiety/PTSD identified by clinical scales, with suicidal ideation present but no intent or plan.
Eligibility Criteria
Inclusion Criteria: 1. 18-69 years old 2. Have been on a stable psychiatric medication regimen for at least four weeks prior to study participation. 3. Formal diagnosis of major depressive disorder or post-traumatic stress disorder by a mental health professional. 4. Must be under the care of a medical provider (ex: primary care, therapist, psychiatrist, psychiatric nurse practitioner) for mental health treatment who can provide contact information and written confirmation that they will be willing and able to care for participant during their entire involvement in the study. Exclusion Criteria: 1. A prior history of other central nervous system disease or any history of seizures; 2. history of psychotic disorders (e.g., schizophrenia, schizoaffective disorder, bipolar disorder type I); 3. history of current or recent (within one year) substance/alcohol use disorder, with the exception of tobacco use disorder; 4. meet criteria for Very High risk of suicide, or require inpatient hospital-level care for psychiatric reasons at time of consent, to reduce exacerbation of risk of harm to self during study; 5. presence of any implanted metal or electrical device (e.g. pacemaker); 6. recent medical hospitalization (within three weeks); 7. any condition that would prevent the participant from completing the protocol, such as significant agitation; 8. appointment of a legal representative or treatment guardian; 9. any ongoing litigation related to a health condition; 10. any other contraindication to exposure to strong magnetic fields or MRI, such as severe claustrophobia; 11. pregnancy or lactation; 12. a family history of schizophrenia or schizoaffective disorder (first or second degree relatives), or bipolar disorder type 1 (first degree relatives), to reduce risk of exacerbation of an undiagnosed psychotic condition; 13. other medical conditions that would preclude safe participation in the trial (e.g., decompensated heart failure); 14. starting or planning to start psychotherapy or changing the frequency or intensity of existing psychotherapy during the trial (current psychotherapy can be continued provided the frequency and intensity has been stable for ≥2 months prior to screening); 15. membership in a vulnerable population (minors, prisoners); 16. any contraindication for blood draws. Arm 1: Inclusion: 1. PRE-EMPT Risk Level Low or Intermediate (recent suicidal ideation, but no intent/plan; C-SSRS level low; mild-to-moderate depression (QIDS score 6-15) or PTSD (PCL-5 score 20-32)) 2. Right-handed. Arm 2: Inclusion: 1\) PRE-EMPT Risk Level Intermediate or High (recent suicidal ideation, but no intent or plan; C-SSRS level low to moderate; moderate to severe depression (QIDS score \>16) or PTSD (PCL-5 score greater than or equal to 33)) Arm 3: Inclusion: 1\) PRE-EMPT Risk Level Intermediate or High (recent suicidal ideation, but no intent or plan; C-SSRS level low to moderate; moderate to severe depression (QIDS score ≥16) or PTSD (PCL-5 score greater than or equal to 33)) Exclusions: 1. Other additional medical conditions that would preclude safe participation in this arm of the trial: 1. significantly impaired liver function, 2. severe coronary artery disease, 3. heart failure, 4. uncontrolled hypertension (above 140/90 mmHg upon screening) , i. If blood pressure is consistently elevated \> 140/90 mmHg across 3 attempts, subjects may be referred to their primary care provider for management of hypertension. Upon management of blood pressure, subjects will have an opportunity to return once within the 30 day screening window to make 3 additional attempts at a blood pressure reading ≤ 140/90 mmHg. Subjects will be considered eligible upon registering 1 blood pressure reading ≤ 140/90 mmHg during the screening period. Blood pressure will be reassessed on Day 0 prior to dosing, and must be less than or equal to 140 systolic, 90 diastolic, with resting pulse ≤ 100 (ascertained within 20 minutes of IP administration in order for the participant to receive study medication.) e. history of cerebrovascular accident, f. severe obesity (BMI ≥ 35), g. untreated asthma, h. untreated hyperthyroidism, i. narrow-angle glaucoma, j. stenosing peptic ulcer, k. pyloroduodenal obstruction, l. symptomatic prostatichypertrophy, or m. bladder-neck obstruction, n. history of valvular heart disease or any heart condition that affects the valves 2. serious ECG abnormalities (e.g., evidence of ischemia, myocardial infarction, QT interval corrected for heart rate \[QTc\] prolongation (QTc \> 0.45 seconds), arrhythmia, or conduction abnormalities that increase the risk of arrhythmia); 3. allergy or hypersensitivity to psilocybin or chocolate
Optimizing Brain Excitability in Depression
NCT07242105
Recruiting
Conditions Major Depressive Disorder
Phase NA
Enrollment 145
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Device: Active Single-Pulse TMS — Single-pulse transcranial magnetic stimulation is delivered to the left dorsolateral prefrontal cortex using a MagVenture X100 stimulator and B65 A/P coil across predefined locations, coil angles, and stimulation intensities.
  • Device: Sham Single-Pulse TMS — Sham single-pulse TMS is delivered using a flipped coil and concurrent scalp electrical stimulation to mimic auditory and somatosensory sensations without producing cortical stimulation.
  • Device: TARGET-optimized TMS — Single-pulse TMS parameters (location, angle, and intensity) are adjusted in real time using the TARGET closed-loop algorithm based on concurrent EEG measurements to deliver optimized stimulation.
  • Device: Non-optimized (Open-Loop) TMS — Single-pulse TMS is delivered using a predefined open-loop set of stimulation parameter combinations across multiple dlPFC locations, coil angles, and intensities without real-time adjustment.
  • Other: EEG Recording — Participants undergo concurrent 64-channel TMS-compatible scalp EEG recording during stimulation to measure TMS-evoked neural responses.
  • Other: Intracranial EEG (iEEG) Recording — Neurosurgical participants undergo intracranial EEG recording using clinically implanted electrodes during TMS to measure local and downstream neural activity.

Primary Outcomes

  • Changes in Anterior EL-TEP Amplitude after single-pulse TMS (spTMS) (Baseline, end of spTMS (6 hours))
  • Changes in Posterior EL-TEP Amplitude after spTMS (Baseline, end of spTMS (6 hours))
  • Changes in intracranial TMS-Evoked Potential (iTEP) Amplitude after TMS-iEEG (Baseline, end of spTMS (20 minutes))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-23
Completion: 2029-11-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 145 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Corey J Keller, MD, PhD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Jade T Truong, BS
408-840-3313
kellerlab@stanford.edu
Interventions
  • Device: Active Single-Pulse TMS — Single-pulse transcranial magnetic stimulation is delivered to the left dorsolateral prefrontal cortex using a MagVenture X100 stimulator and B65 A/P coil across predefined locations, coil angles, and stimulation intensities.
  • Device: Sham Single-Pulse TMS — Sham single-pulse TMS is delivered using a flipped coil and concurrent scalp electrical stimulation to mimic auditory and somatosensory sensations without producing cortical stimulation.
  • Device: TARGET-optimized TMS — Single-pulse TMS parameters (location, angle, and intensity) are adjusted in real time using the TARGET closed-loop algorithm based on concurrent EEG measurements to deliver optimized stimulation.
  • Device: Non-optimized (Open-Loop) TMS — Single-pulse TMS is delivered using a predefined open-loop set of stimulation parameter combinations across multiple dlPFC locations, coil angles, and intensities without real-time adjustment.
  • Other: EEG Recording — Participants undergo concurrent 64-channel TMS-compatible scalp EEG recording during stimulation to measure TMS-evoked neural responses.
Study Locations (2 sites)
University of Iowa, Iowa City, California 52246 United States
Stanford University, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * Men and women, ages 18 to 65 * Diagnosis of major depressive disorder, assessed through a Structured Clinical Interview for DSM-5 (SCID-5) * In a current depressive episode, assessed through a Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (SCID-5) * Moderate-to-severe depression as indicated by a score between 11-20 on the Quick Inventory of Depressive Symptoms (QIDS) * Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales * No current or history of neurological disorders * No seizure disorder or risk of seizures * Neurosurgical patients: Men and women ages 18-65 with medication-refractory epilepsy who are admitted for phase II intracranial monitoring to detect a seizure focus will be considered appropriate for this study. Participants must have the intellectual capacity to understand the consent process and agree to the study. Exclusion Criteria: * Those with a contraindication for MRIs (e.g. implanted metal) * History of head trauma with loss of consciousness * History of seizures or on medications that reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium) * Neurological or uncontrolled medical disease * Any unstable medical condition * Active substance abuse * Diagnosis of psychotic or bipolar disorder * A prior history of Electroconvulsive Therapy (ECT) failure * History of suicide attempt in the past year * Currently pregnant or breastfeeding * Repetitive Transcranial Magnetic Stimulation (rTMS) treatment in the past six months
Technology dRiven Enhancement to Engage & Connect
NCT06910683
Not yet recruiting
Conditions Depression
Phase NA
Enrollment 60
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study will investigate whether an intervention that includes remotely delivered therapy sessions and a digital mental health app, compared to only remotely delivered therapy reduces late-life depression

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: TREE-Connect — TREE-Connect is a mental health app that aims to increase engagement in rewarding activities
  • Behavioral: Clinician-delivered psychotherapy — Clinician-delivered psychotherapy is delivered remotely and aimed to increase engagement in rewarding activities

Primary Outcomes

  • Acceptability (Client Satisfaction Questionnaire; CSQ) (9 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2027-03
Completion: 2029-03
Eligibility
Age: 50 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Principal Investigators:
  • Nili Solomonov, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
  • Samprit Banerjee, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Delaney Callaghan, BA
1-781-999-3731
dec4018@med.cornell.edu
Maddy Schier, BA
1-484-354-1131
mas4019@med.cornell.edu
Interventions
  • Behavioral: TREE-Connect — TREE-Connect is a mental health app that aims to increase engagement in rewarding activities
  • Behavioral: Clinician-delivered psychotherapy — Clinician-delivered psychotherapy is delivered remotely and aimed to increase engagement in rewarding activities
Study Locations (1 sites)
Weill Cornell Medicine, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 50-80 * Capacity to provide consent for research assessment and treatment. * Significant depression, i.e., PHQ-9 ≥ 7 (mild-moderate severity of symptoms) * Mini Mental Status Exam (MMSE) equal or greater than a score of 23. * Off antidepressants or on stable dose for 8 weeks and do not intend to change the dose in the next 10 weeks, without individual psychotherapy services during the study period. Exclusion Criteria: * Intent or plan to commit suicide in the near future. * Inability to communicate in English. * History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, generalized anxiety disorder, specific phobia, or antisocial or borderline personality disorder. * Neurological disorders (dementias, amnestic and multidomain Mild Cognitive Impairment, Parkinson's disease, epilepsy, etc.). * Acute or severe medical illness in the past 3 months (metastatic cancer, multiple sclerosis, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction, cardiac, renal, or respiratory failure; severe chronic obstructive pulmonary disease, etc.) that may be the primary cause depressive symptoms, influence brain systems of interest, or impact ability to participate in the study. * For MRI only: Contraindications to MRI scanning including cardiac pacemaker, heart valve replacement, vascular stent, insulin pump, cochlear implant, any other metallic biomedical implant contraindicating to MRI, and claustrophobia.
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
NCT05660642
Recruiting
Conditions Treatment Resistant Depression
Phase PHASE2
Enrollment 72
Locations 3 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive therapy with defined SSRIs (citalopram, escitalopram, sertraline or fluoxetine).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BPL-003 — Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)

Primary Outcomes

  • 1. To assess the safety and tolerability of single or multiple intranasal doses of BPL-003 in patients with treatment resistant depression (Baseline to 12 weeks post dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-02-10
Completion: 2026-11
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beckley Psytech Limited
Principal Investigators:
  • Kevin Craig, M.D. (STUDY_DIRECTOR) - Beckley Psytech Ltd
Contact Information
Study Contact:
Kevin Craig, M.D.
332-282-0507
clinicaltrials@ataibeckley.com
Interventions
  • Drug: BPL-003 — Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
Study Locations (3 sites)
MAC Clinical Research, Liverpool, L34 1BH United Kingdom
Hammersmith Medicines Research, London, United Kingdom
King's College London, Clinical Trials Facility, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with Major Depressive Disorder. 2. Diagnosed with TRD defined as failure to respond to an adequate dose and duration of at least 2 pharmacological treatments in the past 5 years prior to screening, at least one of which is during the current episode. 3. Montgomery-Asberg Depression Rating Scale score ≥24 at Screening. 4. Clinical Global Impression - Severity ≥4 at Screening. 5. Willing and able to discontinue current pharmacological anti-depressant therapy. 6. On current stable dose of pharmacological antidepressant therapy limited to one of 4 SSRIs (Arm B), i.e. either citalopram, escitalopram, sertraline or fluoxetine. Exclusion Criteria: 1. Current or history of schizophrenia, psychotic disorder including psychotic depression, bipolar disorder, delusional disorder, schizoaffective disorder, or any other severe psychiatric disorder. 2. Current personality disorders. 3. First-degree family history of schizophrenia, bipolar disorder, delusional disorder, personality disorders or schizoaffective disorder. 4. Current alcohol or substance use disorder (other than caffeine or nicotine). 5. A participant who at any time, has been unresponsive to ketamine, esketamine, an adequate course of treatment with electroconvulsive therapy, or has received vagal nerve stimulation or deep brain stimulation. 6. Suicidal ideation with the intent to act or suicidal behaviour within the 12 months prior to the start of Screening or on Day 1 prior to dosing. 7. Suicide attempt and/or self-injurious behaviour within the last 12 months prior to Screening. 8. Uncontrolled medical conditions e.g. hypo/hyperthyroidism, diabetes, renal failure. 9. Seizure disorder or history of seizures (including febrile seizures). 10. Abnormal and clinically significant results on the physical examination, vital signs, electrocardiogram, or laboratory tests at Screening Baseline. 11. Any nasal obstruction, blockage, or symptoms of congestion at the time of dosing, that in the Investigator's opinion may interfere with administration of the study drug. 12. Currently receiving lithium, antipsychotics, serotonergic drugs (excluding the permitted SSRIs for arm B), psychostimulants, or any other prohibited medication. 13. Female patients who are pregnant or lactating, or of childbearing potential and not willing to use adequate forms of contraception. 14. Male patients who are sexually active and not willing to using adequate forms of contraception.
The Effects of Chin Tuck Against Resistance Exercise on Acute Stroke Patients With Dysphagia
NCT06674356
Recruiting
Conditions Acute Stroke, Dysphagia
Phase NA
Enrollment 74
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to investigate the effects of chin tuck against resistance exercise on swallowing function, depression, and quality of life in acute stroke patients with dysphagia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: chin tuck against resistance exercise — Both groups of patients will receive traditional swallowing rehabilitation therapy; however, the experimental group will additionally perform CTAR exercises. The procedure is as follows:Ask the patient to sit, then, press the chin firmly against the inflatable rubber ball, for isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. And for isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions. Performing both isometric and isotonic exercises constitutes one set of exercises. For isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. For isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions.

Primary Outcomes

  • swallowing function (before intervention and up to 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-22
Completion: 2027-10
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 74 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Contact Information
Study Contact:
Fang-Ju Lin
+886-23123456
linfunzoe@ntuh.gov.tw
Interventions
  • Behavioral: chin tuck against resistance exercise — Both groups of patients will receive traditional swallowing rehabilitation therapy; however, the experimental group will additionally perform CTAR exercises. The procedure is as follows:Ask the patient to sit, then, press the chin firmly against the inflatable rubber ball, for isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. And for isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions. Performing both isometric and isotonic exercises constitutes one set of exercises. For isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. For isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions.
Study Locations (1 sites)
Department of Nursing, National Taiwan University, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with hemorrhagic or ischemic stroke, including those with initial diagnoses or recurrent strokes. 2. Patients who did not pass the swallowing screening based on the standard swallowing scale. 3. Adults aged 18 years and older. 4. Vital signs are stable: systolic blood pressure (hemorrhagic \< 160 mmHg, ischemic \< 220 mmHg), heart rate 40-130 beats per minute, and oxygen saturation \> 92%. 5. The patient's consciousness is clear, able to express themselves, can communicate in Mandarin or Taiwanese, and can follow commands to perform actions. 6. The patient can be in a seated position. Exclusion Criteria: 1. Patients who have had a stroke for more than one month (inclusive). 2. Patients with a history of depression or related mental health disorders. 3. Patients with a history of neck pain, injury, or disease. 4. Patients who have previously undergone tracheostomy or have a tracheostomy tube in place.
Observations of a Brief Online Psychological Intervention Among People Seeking Online Mental Health Services
NCT06178328
Recruiting
Conditions Depression, Anxiety
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Since 2012, the Online Therapy Unit has been offering Internet-delivered cognitive behaviour therapy (ICBT). ICBT represents a convenient method for individuals to access care for depression and anxiety. In ICBT, clients receive access to standardized lessons that provide the same information and skills as traditional face-to-face CBT. ICBT courses often span 6-12 weeks. There is now growing evidence that clients with symptoms of depression and anxiety can benefit from a single session brief intervention that offers practical strategies for improving mental health, but the investigators are uncertain about the interest in such a lesson among those seeking online mental health care. The Things You Do Course, therefore, is designed to provide clients with 5 key actions that clients can take to improve their emotional wellbeing. In this study, the Online Therapy Unit (OTU) is examining how effective the Things You Do Course is in helping clients manage their symptoms of depression and anxiety and improve their emotional wellbeing. The OTU is also exploring the extent to which clients are satisfied with the course, and what factors contribute to improvements in symptoms, as measured by a number of questionnaires. The research will ultimately be used to improve how the OTU will deliver ICBT and to inform whether to include the single session course within existing online mental health service options.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Things You Do Course — Participants receiving the brief psychological intervention ('Things You Do' Course) will have access to a single online lesson that includes course materials and printable materials (i.e., an activity guide and planner) that can be retained for longer-term use. The course materials include an introduction to the purpose and content of the course, education about factors that impact mental health, and information about the 'Big Five' things participants can do to improve their mental health. Participants will also receive automated no-reply emails (5 days/week) through the intervention platform to remind them to practice the skills from the course.

Primary Outcomes

  • The Things You Do Questionnaire - 21 item (TYD-Q) (Pre-treatment, 2 weeks (mid-treatment), 4 weeks (post-treatment), and 17 weeks (follow-up))
  • Patient Health Questionnaire (PHQ-9) (Pre-treatment, 2 weeks (mid-treatment), 4 weeks (post-treatment), and 17 weeks (follow-up))
  • Generalized Anxiety Disorder 7-Item (GAD-7) (Pre-treatment, 2 weeks (mid-treatment), 4 weeks (post-treatment), and 17 weeks (follow-up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-17
Completion: 2026-09
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Regina
Principal Investigators:
  • Heather Hadjistavropoulos, PhD (PRINCIPAL_INVESTIGATOR) - University of Regina
Contact Information
Study Contact:
Heather Hadjistavropoulos, PhD
306-585-5133
hadjista@uregina.ca
Marcie Nugent, MSW
306-337-3331
marcie.nugent@uregina.ca
Interventions
  • Behavioral: Things You Do Course — Participants receiving the brief psychological intervention ('Things You Do' Course) will have access to a single online lesson that includes course materials and printable materials (i.e., an activity guide and planner) that can be retained for longer-term use. The course materials include an introduction to the purpose and content of the course, education about factors that impact mental health, and information about the 'Big Five' things participants can do to improve their mental health. Participants will also receive automated no-reply emails (5 days/week) through the intervention platform to remind them to practice the skills from the course.
Study Locations (1 sites)
Online Therapy Unit- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
Eligibility Criteria
Inclusion Criteria: * Canadian resident; * Aged 18 years or older; * Seeking services for mental health concerns Exclusion Criteria: * Living outside of Canada * Unable to read and understand English
Digital Rewards and Retention in a M-health App
NCT06883773
Not yet recruiting
Conditions Transdiagnostic Psychopathology, Attriti...
Phase NA
Enrollment 177
Locations 1 sites
Compensation incentive available
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Attrition and user engagement are two challenges that eHealth interventions struggle with. Attempts to address this have been previously made through gamification, instructional design and using different types of incentives. Overall, any type of reward, be it non-financial or monetary is better than the controls, but the latter usually produce a greater effect. It is also worth mentioning that having an affective value attached to the reward itself is also important to user retention and engagement. Given the ever-increasing interest in cryptocurrency and its current relevance, the present study - a randomized clinical trial with three arms - aims to compare cryptocurrency to non-monetary rewards regarding their effectiveness in reducing attrition and increasing engagement. In order to do this, a mental-health computerized intervention will be developed, in which the users will have to complete several modules, during which time they will be rewarded either with cryptocurrency, sweepstake rewards (e.g., vouchers), or nothing.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Multipurpose Online Tool — The intervention consists of 6 psychoeducational modules, on the Canvas teaching platform. They are automated, requiring no interaction with others (except for communication between participants and the team). Participants go through the psychoeducational modules, then do the corresponding exercise, and then access their rewards (if they belong to the experimental or comparative groups).
  • Other: No intervention — The participants will be assessed but without any intervention

Primary Outcomes

  • Participant retention (From enrollment to the end of the 6 week intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-03-15
Completion: 2025-09-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 177 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Bucharest
Contact Information
Study Contact:
Cezar Giosan, PhD
+40730908050
giosan@outlook.com
Interventions
  • Behavioral: Multipurpose Online Tool — The intervention consists of 6 psychoeducational modules, on the Canvas teaching platform. They are automated, requiring no interaction with others (except for communication between participants and the team). Participants go through the psychoeducational modules, then do the corresponding exercise, and then access their rewards (if they belong to the experimental or comparative groups).
  • Other: No intervention — The participants will be assessed but without any intervention
Study Locations (1 sites)
University of Bucharest, Bucharest, Romania
Eligibility Criteria
Inclusion Criteria: * English speaking Exclusion Criteria: \-
Filipino Family Health Initiative 1.0
NCT06569303
Recruiting
Conditions Depression, Anxiety, Parenting
Phase NA
Enrollment 500
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test the effectiveness of an online parenting program on Filipino parents living in California. The main aims are to: * Test the effectiveness of the online Incredible Years® model of parent training and its impact on primary outcomes. * Determine the impact of intervention engagement (i.e., higher attendance) on parenting practices and child behavior outcomes. * Describe Intervention delivery and its online implementation in real-world community settings. The study involves two phases: * Phase 1: Participants will receive the Online Incredible Years® School Age Basic \& Advanced Parent Training Program (intervention) and complete parent-reported and child-reported measures at baseline, 3 months and 6 months. * Phase 2: Parenting Group Leaders will each participate in one semi-structured interview to inform the sustainability of the intervention in real world community settings. Researchers will compare 250 Filipino families, half of which will receive the intervention and the other half will receive the American Academy of Pediatrics' Bright Futures handouts (control) and be placed on a 3-month waitlist for the IY parenting program. Both groups will be followed for a minimum of 6 months with follow- up assessments that include parent-report and child report measures.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Incredible Years® School Age Basic Parent Training Program — The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
  • Behavioral: American Academy of Pediatrics, Bright Futures Handouts — Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.

Primary Outcomes

  • Parent Reported Positive Verbal Discipline (Baseline, 3 months, 6 months)
  • Child Reported Depression Symptoms (Baseline, 3 months, 6 months)
  • Child Reported Anxiety Symptoms (Baseline, 3 months, 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-15
Completion: 2028-03-31
Eligibility
Age: 8 Years
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kaiser Permanente
Collaborators: Children's Hospital Los Angeles, University of Southern California, University of California, San Diego, National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Joyce R Javier, MD MPH MS (PRINCIPAL_INVESTIGATOR) - Kaiser Permanente School of Medicine
Contact Information
Study Contact:
Joyce R Javier, MD MPH MS
626-862-7072
joyce.r.javier@kp.org
Lindsey R Thompson, MS, MPH
lindsey.r.thompson@kp.org
Interventions
  • Behavioral: Incredible Years® School Age Basic Parent Training Program — The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
  • Behavioral: American Academy of Pediatrics, Bright Futures Handouts — Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
Study Locations (1 sites)
Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101 United States
Eligibility Criteria
Inclusion Criteria: * Parent or legal guardian of at least one child 8-12 years of age * Parent or legal guardian is of Filipino descent * Parent or legal guardian and child are English speaking * Pregnant women or legal guardians may be included if they have a child who meets the inclusion and exclusion criteria Exclusion Criteria: * Family plans to move out of the state of California within the next 6 months * Family has previously participated in the Incredible Years (IY) curriculum * Parent or legal guardian are not fluent in English * Adults unable to consent or children unable to assent * Prisoners Note: All parent participants in the study are 18 years or older. Youth participants are 8-12 years old.
Evaluating the Effectiveness of an Internet-based Therapy (iCARE) to Treat Symptoms of Postpartum Depression
NCT07384273
Recruiting
Conditions Postpartum Depression (PPD)
Phase NA
Enrollment 352
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Postpartum depression (PPD) is a common and serious condition affecting 9.5% of women in high-income countries, and around 8% in Denmark. It shares core features with major depression, including low mood, loss of interest, and impaired functioning. Untreated PPD can persist for months, negatively impacting maternal well-being, child development, and family dynamics. In Denmark, systematic screening using the Edinburgh Postnatal Depression Scale (EPDS) is standard practice, but access to PPD treatment varies widely across municipalities. Cognitive behavioral therapy (CBT) is the most effective psychological intervention for perinatal depression, yet limited availability and long wait times create barriers to access to care. Internet-based CBT (iCBT) offers a scalable, cost-effective alternative that can be delivered flexibly at home. Evidence supports the efficacy of self-guided iCBT for depression, though challenges such as high dropout rates have been reported. International trials in Norway, Portugal, Iran, South Korea, and the US have shown promising results for iCBT in perinatal populations. Some recent iCBT based interventions have also incorporated elements of Acceptance and Commitment Therapy (ACT) - which emphasizes psychological flexibility via mindfulness-based acceptance and values-driven action-and have demonstrated efficacy in reducing postpartum depression symptoms. These kinds of interventions (either iCBT or iCBT + ACT) have not yet been tested and evaluated in Denmark. This clinical trial aims to evaluate whether adding an iCBT intervention with elements from ACT (iCARE) to treatment as usual (TAU) is more effective than TAU alone in reducing depressive symptoms in mothers with symptoms of PPD. Moreover, a qualitative process evaluation of the iCARE will explore implementation, acceptability, and mechanisms of impact. Its primary aim is to understand how participants experience the iCARE intervention and TAU, focusing on implementation fidelity, acceptability, and contextual influences. The secondary aim is to explore perceived mechanisms of change (e.g., cognitive, emotional, behavioral) and barriers/facilitators to engagement.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Internet-based therapy (iCARE) and treatment as usual — The iCARE program is a self-guided iCBT intervention that also incorporates selected exercises and approaches from ACT. The iCARE program consists of four core modules and four optional modules. Together, these exercises aim to enhance psychological flexibility, reduce negative thinking, and promote well-being in daily life. The core modules focus on self-care and mindfulness (Module 1), identifying and reframing unrealistic expectations with self-compassion (Module 2), increasing positive experiences and countering self-critical thoughts (Module 3), and recognizing and challenging thinking traps (Module 4). The additional optional modules provide strategies for practicing being present, communicating needs and asking for support, bonding with the baby, and coping with scary thoughts.
  • Other: Treatment as usual (TAU) — In Denmark, there is large variation in the available prevention and treatment municipalities offers for women experiencing symptoms of PPD. Some municipalities offer specialized psychological support and support groups, while others provide only basic follow-up by health nurses. Women can also be referred to their general practitioner, who can provide free ongoing follow-up and prescribe antidepressant medication if needed. Alternatively, it is possible to be referred to a privately practicing psychologist, usually with some out-of-pocket cost.

Primary Outcomes

  • Symptoms of postpartum depression (Baseline At 2 months (primary endpoint) At 6 months (secondary endpoint))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-01
Completion: 2028-08-01
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 352 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern Denmark
Collaborators: University of Copenhagen, Odense University Hospital
Contact Information
Study Contact:
Trine Munk-Olsen, PhD
+4524466297
tmun@sdu.dk
Interventions
  • Behavioral: Internet-based therapy (iCARE) and treatment as usual — The iCARE program is a self-guided iCBT intervention that also incorporates selected exercises and approaches from ACT. The iCARE program consists of four core modules and four optional modules. Together, these exercises aim to enhance psychological flexibility, reduce negative thinking, and promote well-being in daily life. The core modules focus on self-care and mindfulness (Module 1), identifying and reframing unrealistic expectations with self-compassion (Module 2), increasing positive experiences and countering self-critical thoughts (Module 3), and recognizing and challenging thinking traps (Module 4). The additional optional modules provide strategies for practicing being present, communicating needs and asking for support, bonding with the baby, and coping with scary thoughts.
  • Other: Treatment as usual (TAU) — In Denmark, there is large variation in the available prevention and treatment municipalities offers for women experiencing symptoms of PPD. Some municipalities offer specialized psychological support and support groups, while others provide only basic follow-up by health nurses. Women can also be referred to their general practitioner, who can provide free ongoing follow-up and prescribe antidepressant medication if needed. Alternatively, it is possible to be referred to a privately practicing psychologist, usually with some out-of-pocket cost.
Study Locations (1 sites)
Research Unit of Child and Adolescent Psychiatry, Department of Clinical Research, University of Southern Denmark, Odense, 5250 Denmark
Eligibility Criteria
Inclusion Criteria: * Given birth within 6 months * Edinburgh Postnatal Depression Scale (EPDS) score above 7 * ≥age 18 * Access to the internet Exclusion Criteria: * Do not understand Danish language, * Substance abuse or dependence * Alcohol abuse, defined by a weekly consumption of alcohol exceeding 10 units * A diagnosis of schizophrenia, other psychotic disorders or in immediate need of psychiatric treatment.
Comparing Integrative Midwife-led vs. Fragmented Inpatient Postpartum Care: Impact on Satisfaction and Transition to Motherhood
NCT07077941
Not yet recruiting
Conditions Maternal Health Services, Infant, Newbor...
Phase NA
Enrollment 784
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-09
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare two different forms of postnatal care to find out which is most beneficial for mothers and their children after birth and with which they are most satisfied. One is a nurse-led, seperate model of care and the other is a midwife-led, integrative model of care. Participants are healthy women between the ages of 18 and 50. They gave birth between 36+0 and 42+0 weeks of pregnancy and had a child. The type of birth is not an inclusion or exclusion criteria. Our hypotheses are: i) that maternal satisfaction with care in a midwife-led, integrative care model is higher than in separate maternal and infant care; ii) that a positive postpartum experience leads to earlier and increased maternity competence; iii) that a higher breastfeeding rate at the time of the survey in the fourth month can be achieved through integrative care. Participants will be randomly assigned, after birth of their child, to either the group cared for by a nurse or the group cared for by a midwife.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Integrative care — Joint care of mother and child by just one healthcare professional

Primary Outcomes

  • Maternal Functioning 1a (within 3 days postpartum)
  • Maternal Functioning 1b (Approximately 28 days postpartum)
  • Maternal Functioning 1c (Approximately 120 days postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-10-01
Completion: 2026-12-31
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 784 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Vienna
Principal Investigators:
  • Tanja A. Stamm, PhD (PRINCIPAL_INVESTIGATOR) - Institute for Outcomes Research Center for Medical Data Science Medical University of Vienna
  • Alex Farr, PhD (STUDY_DIRECTOR) - Medical University of Vienna, Dept. of Obstetrics and Gynecology, Division of Feto-Maternal Medicine
Contact Information
Study Contact:
Vera E. Eschenbach, MSc
+43 69919438971
vera.eschenbach@gmx.at
Alex Farr, PhD
0043-1-40400
alex.farr@meduniwien.ac.at
Interventions
  • Other: Integrative care — Joint care of mother and child by just one healthcare professional
Study Locations (1 sites)
General Hospital Vienna; Department of Obstetrics and Feto-Maternal Medicine Head of the Department of Gynaecology, Vienna, State of Vienna 1090 Austria
Eligibility Criteria
Inclusion Criteria: * Women aged 18 to 50 years at the time of delivery * Classified as "low-risk" by the obstetric team in the delivery room * Gestational age at birth between 36+0 and 42+0 weeks * Singleton birth (only one child born) * Intent to breastfeed * Consent to participate in the study Exclusion Criteria: * Women younger than 18 or older than 50 at the time of delivery * Classified as "high-risk" by the obstetric team * Multiple birth (e.g., twins, triplets) * No intention or ability to breastfeed the newborn